Modified release paracetamol overdose: a prospective observational study (ATOM-3)

• Published in: Clinical toxicology (Philadelphia, Pa.) Vol. 56; no. 9; pp. 810 - 819
• Main Authors: Chiew, Angela L., Isbister, Geoffrey K., Page, Colin B., Kirby, Katharine A., Chan, Betty S. H., Buckley, Nicholas A.
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 02.09.2018
• Subjects: Acetaminophen - poisoning; activated charcoal; Adult; Analgesics, Non-Narcotic - poisoning; Australia; Charcoal - therapeutic use; Chemical and Drug Induced Liver Injury - drug therapy; Chemical and Drug Induced Liver Injury - etiology; Delayed-Action Preparations - poisoning; Dose-Response Relationship, Drug; Drug Overdose - drug therapy; Female; hepatotoxicity; Humans; Male; Middle Aged; modified-release acetylcysteine; overdose; Paracetamol; Prospective Studies; Retrospective Studies; Young Adult; Australia; overdose; modified-release acetylcysteine; Paracetamol; activated charcoal; hepatotoxicity
• ISSN: 1556-3650; 1556-9519
• DOI: 10.1080/15563650.2018.1439950

Background: Modified-release (MR) paracetamol is available in many countries as 665 mg tablets of which 69% is MR and 31% is immediate release. There are concerns that MR paracetamol overdose has higher rates of liver injury despite standard treatment algorithms. The objective of this study was to describe the clinical characteristics and outcomes of acute MR paracetamol overdose. Methods: Prospective observational study, recruiting patients from January 2013 to June 2017, from five clinical toxicology units and calls to two Poisons Information Centres in Australia. Included were patients >14 years who ingested ≥10 g or 200 mg/kg (whichever is less) of MR paracetamol. Data collected included demographics, ingestion history, pathology results, treatments, and outcomes including hepatotoxicity (ALT >1000 U/L). Results: In total, 116 patients were recruited, 85(73%) were female. The median dose ingested was 32 g (IQR: 20-49 g) and median time to presentation was 3 h (IQR: 2-9 h). 78(67%) had an initial paracetamol concentration above the nomogram line (150 mg/L at 4 h). A further 12(10%) crossed the nomogram after repeat paracetamol measurements, of which five crossed after two non-toxic levels 4 h apart. Six had a double paracetamol peak, in three occurring >24 h post-ingestion. 113(97%) received acetylcysteine of which 67 received prolonged treatment beyond the standard 21 h. This was because of an elevated paracetamol concentration at the completion of acetylcysteine in 39 (median paracetamol concentration 25 mg/L, IQR: 16-62 mg/L). 21 (18%) developed hepatotoxicity, including six treated within 8 h of ingestion. Activated charcoal and double doses of acetylcysteine did not significantly decrease the risk of hepatotoxicity. Conclusions: Drug regulatory authorities are considering restrictions on MR paracetamol preparations. Following an acute MR paracetamol overdose, this study found that many patients had a persistently elevated paracetamol concentrations, many required prolonged treatment and some developed liver injury despite early acetylcysteine treatment. Furthermore, activated charcoal and increased acetylcysteine did not appear to significantly alter the risk of liver injury. Hence, research into better treatment strategies is required. Trial registration: Australian Toxicology Monitoring (ATOM) Study - Australian Paracetamol Project: ACTRN12612001240831 (ANZCTR) Date of registration: 23/11/2012.